2025

First and co-first author publications

Kokkorakis M*, Folkertsma P*, Anagnostakis F*, Sirotin N, Agarwal M, Shantouf R, Henning RH, Pijl H, Wolffenbuttel BHR, Bax JJ, Astma DE, Forte JC, Mantzoros CS, van Dam S (2025) Simplifying coronary artery disease risk stratification: development and validation of a questionnaire-based alternative comparable to clinical risk tools . EBioMedicine 111:105518.

Kokkorakis M*, Folkertsma P*, Castela Forte J, Wolffenbuttel BHR, van Dam S, Mantzoros CS (2025) GDF-15 improves the predictive capacity of steatotic liver disease non-invasive tests for incident morbidity and mortality risk for cardio-renal-metabolic diseases and malignancies . Metabolism 163:156047.

Co-authored publications

Anagnostakis F, Kokkorakis M, Asvestis C, Papadimopoulos I, Nagarajan S, Talbot K, Li L, Chen Y, Nasrallah IM, Wen J, Davatzikos C (2025) Impact of cardiometabolic conditions on the progression from mild cognitive impairment to dementia: a large cohort study . Alzheimer’s & Dementia 21:e70692.

Anagnostakis F, Kokkorakis M, Walker KA, Skampardoni I, Wen J, Erus G, Tosun D, Tassopoulou V, Cui Y, Govindarajan ST, Srinivasan D, Melhem R, Mamourian E, Shou H, Nasrallah IM, Mantzoros CS, Davatzikos C (2025) Radiomic and proteomic signatures of body mass index on brain ageing and Alzheimer’s-like patterns of brain atrophy . EBioMedicine 116:105763.

2024

First and co-first author publications

Kokkorakis M*, Chakhtoura M*, Rhayem C§, Al Rifai J§, Ghezzawi M, Valenzuela-Vallejo L, Mantzoros CS (2024) Emerging Pharmacotherapies for Obesity: A Systematic Review . Pharmacological Reviews 77:100002.

Stefanakis K*, Kokkorakis M*, Mantzoros CS (2024) The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation . Metabolism 161:156057.

Kokkorakis M*, Boutari C*, Hill MA, Kotsis V, Loomba R, Sanyal AJ, Mantzoros CS (2024) Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges . Metabolism 154:155835.

Co-authored publications

Anagnostakis F, Kokkorakis M, Walker K, Davatzikos C (2024) Signatures and Discriminative Abilities of Multi-Omics between States of Cognitive Decline . Biomedicines 12(5):941.

Kim K*, Kim MM*, Skoufos G, Diffenderfer ES, Motlagh SAO, Kokkorakis M, Koliaki I, Morcos G, Shoniyozov K, Griffin J, Hatzigeorgiou AG, Metz JM, Lin A, Feigenberg SJ, Cengel KA, Ky B, Koumenis C, Verginadis II (2024) FLASH proton radiotherapy mitigates inflammatory and fibrotic pathways and preserves cardiac function in a preclinical mouse model of radiation-induced heart disease . International Journal of Radiation Oncology, Biology, Physics 119(4):1234–1247.

2023

First and co-first author publications

Kokkorakis M*, Folkertsma P, van Dam S, Sirotin N, Taheri S, Chagoury O, Idaghdour Y, Henning RH, Castela Forte J, Mantzoros CS, de Vries DH*, Wolffenbuttel BHR* (2023) Effective questionnaire-based prediction models for type 2 diabetes across several ethnicities: a model development and validation study . eClinicalMedicine 64:102235.

Kokkorakis M*, Katsarou A*, Katsiki N, Mantzoros CS (2023) Milestones in the journey towards addressing obesity: Past trials and triumphs, recent breakthroughs, and an exciting future in the era of emerging effective medical therapies and integration of effective medical therapies with metabolic surgery . Metabolism 148:155689.

Kokkorakis M*, Boutari C*, Katsiki N, Mantzoros CS (2023) From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need . Metabolism 147:155664.

Anagnostakis F*, Kokkorakis M*, Markouji MS, Piperi CS (2023) Impact of Solute Carrier Transporters in Glioma Pathology: A Comprehensive Review . International Journal of Molecular Sciences 24(11):9393.

Co-authored publications

Boutari C, Kokkorakis M, Stefanakis K, Valenzuela-Vallejo L, Axarlaglou E, Volčanšek Š, Chakhtoura M, Mantzoros CS (2023) Recent research advances in metabolism, clinical and experimental . Metabolism 149:155722.

Kouvari M*, Mylonakis SC*, Katsarou A*, Valenzuela-Vallejo L, Guatibonza-Garcia V, Kokkorakis M, Verzatto O, Anjelini G, Markakis G, Eslam M, George J, Papatheodoridis G, Mingrone G, Mantzoros CS (2023) The first external validation of the Dallas steatosis index in biopsy-proven non-alcoholic fatty liver disease: A multicenter study . Diabetes Research and Clinical Practice 203:108770.

Kouvari M*, Valenzuela-Vallejo L*, Guatibonza-Garcia V*, Polyzo S, Deng Y, Kokkorakis M, Agaz M, Mylonakis SC, Katsarou A, Verzatto O, Markakis G, Eslam M, Papatheodoridis G, George J, Mingrone G, Mantzoros CS (2023) Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study . Metabolism 147:155666.

Global Burden of Disease

GBD 2023 Causes of Death Collaborators (2025) Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 . The Lancet [in press].

GBD 2023 Disease and Injury and Risk Factor Collaborators (2025) Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 . The Lancet [in press].

GBD 2023 Demographics Collaborators (2025) Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023 . The Lancet [in press].

Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators (2025) Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990–2023 . JACC [in press].

GBD 2023 Cancer Collaborators (2025) The global, regional, and national burden of cancer, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023 The Lancet 406(10512):1565–1586.

GBD 2023 Vaccine Coverage Collaborators (2025) Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023 . The Lancet 406(10500):235–260.

GBD 2021 Adolescent BMI Collaborators (2025) Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021 . The Lancet 405(10481):785–812.

GBD 2021 Adult BMI Collaborators (2025) Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021 . The Lancet 405(10481):813–838.

PhD Thesis

Kokkorakis M (2025) Evidence-Informed Cardiometabolic Medicine. University of Groningen. Available from: https://doi.org/10.33612/diss.1402979401